Business Wire

CA-NETAPP

7.2.2023 14:02:45 CET | Business Wire | Press release

Share
NetApp Announces New Line of Low-Cost, Capacity Flash Storage for the Modern Data Center

NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the upcoming availability of the NetApp AFF C-Series, a new family of capacity flash storage options that deliver lower cost all-flash storage, and NetApp AFF A150, a new entry-level storage system in the AFF A-Series family of all-flash systems.

The new NetApp AFF C-Series delivers flash performance, while remaining cost-effective and efficient for a lower total cost of ownership (TCO) and a smaller storage footprint. This family of capacity flash arrays are also offered with one of the industry’s most comprehensive software suites, ONTAP One, an all-in-one license that includes all available NetApp software. Customers can modernize their data center with the flexibility to choose the right storage (performance flash, capacity flash, or hybrid) for their VMware, database, and file workload requirements, all running on NetApp ONTAP and managed centrally by NetApp BlueXP for a seamless hybrid cloud experience.

NetApp also announced today, NetApp Advance, a new portfolio of storage programs and guarantees to deliver best-in-class customer ownership experience and cost-effectively future proof on-premises environments.* This gives customers the flexibility and choice to safeguard their storage investment – whether the C-Series, AFF A150 or other newly acquired AFF or FAS systems – with the ability to right-size on-premises environments and transition to storage as a service or cloud storage as their business requires. And with NetApp’s 4:1 Storage Efficiency Guarantee,* NetApp ensures that workload efficiency goals are met, or NetApp will rectify this at no cost to the customer.

“NetApp has been a flash storage leader for years, and today’s announcements of the AFF C-Series and A150 builds on that legacy of innovation to bring our customers and partners some of the most affordable and sustainable all flash storage in the market today,” said Sandeep Singh, Senior Vice President, Enterprise Storage at NetApp. “As companies are looking at their bottom line in this economic environment, we want to meet their needs by providing capacity flash at a lower cost to entry in order to better enable their transition from hybrid storage to all-flash while staying in budget.”

The NetApp AFF C-Series, which is comprised of the AFF C250, AFF C400 and AFF C800, offers:

  • Guaranteed storage efficiency to improve an organization’s storage footprint and energy costs to reduce TCO while simplifying operations.*
  • Seamless scalability on-premises to allow organizations to scale capacity and performance as their data grows.
  • Best-in-class data security with ransomware protection to keep important data secure, available and protected.

The new NetApp AFF A150 is ideal for Mid-size businesses, and Remote Office/Branch Office (ROBO) and distributed deployments to better meet the needs of customers who require entry-level, enterprise-class storage, while providing:

  • Better performance
  • More scalability and expansion options
  • High availability with support for MetroCluster IP

These additions to NetApp’s product line-up are ideal for entry-level to high-end workloads (including virtual machines, database, and backup consolidation), are feature-rich with ONTAP data management, and are offered at an attractive price point for customers – creating strong growth opportunities for NetApp partners to reach new markets while qualifying for NetApp Partner Sphere incentives.

“NetApp continues to assert itself as one of the market’s preeminent innovators for hybrid cloud storage,” said Juan Orlandini, Chief Architect and Distinguished Engineer at Insight Enterprises. “As a leading solutions integrator and longtime NetApp partner, we know our joint customers are looking for the industry’s most innovative solutions and services to enable speed, scale and resilience for their business. With these new capacity flash and entry level offerings, we’re opening the door to acquire new customers at scale.”

NetApp Advance is available today. The NetApp AFF C-Series family and NetApp AFF A150 will be available starting in March 2023, and NetApp and Cisco plan to offer these storage options within the industry-leading integrated infrastructure offering, FlexPod, in Q4 FY’23.

*Terms and conditions will apply.

Additional Resources

About NetApp

NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005482/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye